tiprankstipranks
Trending News
More News >
Clinical Laserthermia Systems AB Class B (SE:CLS.B)
:CLS.B

Clinical Laserthermia Systems AB Class B (CLS.B) Stock Statistics & Valuation Metrics

Compare
0 Followers

Total Valuation

Clinical Laserthermia Systems AB Class B has a market cap or net worth of €80.98M. The enterprise value is kr205.88M.
Market Cap€80.98M
Enterprise Valuekr205.88M

Share Statistics

Clinical Laserthermia Systems AB Class B has 25,663,593 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,663,593
Owned by Insiders
Owned by Institutions

Financial Efficiency

Clinical Laserthermia Systems AB Class B’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -82.32%.
Return on Equity (ROE)-0.69
Return on Assets (ROA)-0.61
Return on Invested Capital (ROIC)-82.32%
Return on Capital Employed (ROCE)-0.83
Revenue Per Employee1.10M
Profits Per Employee0.00
Employee Count17
Asset Turnover0.24
Inventory Turnover2.14

Valuation Ratios

The current PE Ratio of Clinical Laserthermia Systems AB Class B is -0.85. Clinical Laserthermia Systems AB Class B’s PEG ratio is -0.23.
PE Ratio-0.85
PS Ratio0.00
PB Ratio29.58
Price to Fair Value0.59
Price to FCF-5.29
Price to Operating Cash Flow-5.29
PEG Ratio-0.23

Income Statement

In the last 12 months, Clinical Laserthermia Systems AB Class B had revenue of 18.78M and earned -47.62M in profits. Earnings per share was -4.33.
Revenue18.78M
Gross Profit10.42M
Operating Income-54.25M
Pretax Income-47.86M
Net Income-47.62M
EBITDA-44.76M
Earnings Per Share (EPS)-4.33

Cash Flow

In the last 12 months, operating cash flow was -46.39M and capital expenditures -7.47M, giving a free cash flow of -63.92M billion.
Operating Cash Flow-46.39M
Free Cash Flow-63.92M
Free Cash Flow per Share-2.49

Dividends & Yields

Clinical Laserthermia Systems AB Class B pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.19
52-Week Price Change-44.81%
50-Day Moving Average2.89
200-Day Moving Average3.71
Relative Strength Index (RSI)65.26
Average Volume (3m)75.35K

Important Dates

Clinical Laserthermia Systems AB Class B upcoming earnings date is Aug 22, 2025, TBA (Confirmed).
Last Earnings DateMay 16, 2025
Next Earnings DateAug 22, 2025
Ex-Dividend Date

Financial Position

Clinical Laserthermia Systems AB Class B as a current ratio of 2.99, with Debt / Equity ratio of 15.34%
Current Ratio2.99
Quick Ratio2.68
Debt to Market Cap0.00
Net Debt to EBITDA0.50
Interest Coverage Ratio-125.30

Taxes

In the past 12 months, Clinical Laserthermia Systems AB Class B has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Clinical Laserthermia Systems AB Class B EV to EBITDA ratio is -0.40, with an EV/FCF ratio of -0.28.
EV to Sales0.96
EV to EBITDA-0.40
EV to Free Cash Flow-0.28
EV to Operating Cash Flow0.00

Balance Sheet

Clinical Laserthermia Systems AB Class B has €22.51M in cash and marketable securities with kr224.00K in debt, giving a net cash position of -€22.28M billion.
Cash & Marketable Securities€22.51M
Total Debtkr224.00K
Net Cash-€22.28M
Net Cash Per Share-€0.87
Tangible Book Value Per Share€3.98

Margins

Gross margin is 29.17%, with operating margin of -288.85%, and net profit margin of -253.54%.
Gross Margin29.17%
Operating Margin-288.85%
Pretax Margin-254.80%
Net Profit Margin-253.54%
EBITDA Margin-238.28%
EBIT Margin-252.50%

Analyst Forecast

The average price target for Clinical Laserthermia Systems AB Class B is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast86.02%
EPS Growth Forecast93.34%

Scores

Smart ScoreN/A
AI Score47
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis